

# Challenging New Treatment Safety Profile of Neuromyelitis Optica Spectrum Disorder

Claudia Pestchanker \*

Ö^]æ; { ^ } ol [-hP^~; ! [ [ \* ~ÈhP [ • ]ææ; hÜæ { 5 } hÖæ; ! h; [ [ ÈhÜæ } hS ~i • ÈhCE; \* ^ } cæ

**Received:** 06-Jun-2023, Manuscript No. DPO-23-101495; **Editor assigned:** 08-Jun-2023, PreQC No. DPO-23-101495 (PQ); **Reviewed:** 22-Jun-2023, QC No. DPO-23-101495; **Revised:** 29-Jun-2023, Manuscript No. DPO-23-101495 (R); **Published:** 06-Jul-2023, DOI: 10.4172/2476-2024.8.1.216

**Citation:** Pestchanker C (2023) Challenging New Treatment Safety Profile of Neuromyelitis Optica Spectrum Disorder. *Diagnos Pathol Open* 8: 216.

**Copyright:** © 2023 Pestchanker C. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

## Description

Neuromyelitis Optica Spectrum Disorder (NMOSD) is a rare and chronic neuro inflammatory immune-mediated disease of the central nervous system, associated frequently with aquaporin-4 antibodies (AQP4-Ab); initially in the progression of the disorder, demyelinating regions will exhibit symptoms comparable to Multiple sclerosis (such as macrophage/microglia proliferation and axonal injury [1]). Another distinctive aspect of NMO is that axonal damage occurs prior to demyelination.